Quest Laboratories Ltd
Pharmaceuticals & Biotechnology | Small Cap
Quest Laboratories demonstrates a mixed financial performance. Profitability stands out as a significant strength, driven by healthy margins and returns on capital, equity, and assets. Solvency also appears strong, indicating a conservative approach to debt. However, the company faces challenges in liquidity and efficiency, with turnover ratios suggesting potential issues in managing assets and liabilities. Growth metrics reveal a concerning contraction in revenue, EPS, and asset growth in the latest financial year. While coverage ratios are adequate, the absence of dividend coverage raises concerns. The company's strong profitability and solvency are offset by liquidity and efficiency issues. The recent negative growth trends in revenue and earnings are a significant concern that needs attention.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio3.20
- Financial Ratio4.00
- Profitability Ratio10.00
- Efficiency Ratio5.33
- Coverage Ratio5.60
- Solvency Ratio9.00
- Liquidity Ratio3.08
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursBearish
- 1 DayStrong Bearish
- 1 WeekBearish
- 1 MonthNeutral
Quest Laboratories demonstrates a mixed financial performance. Profitability stands out as a significant strength, driven by healthy margins and returns on capital, equity, and assets. Solvency also appears strong, indicating a conservative approach to debt. However, the company faces challenges in liquidity and efficiency, with turnover ratios suggesting potential issues in managing assets and liabilities. Growth metrics reveal a concerning contraction in revenue, EPS, and asset growth in the latest financial year. While coverage ratios are adequate, the absence of dividend coverage raises concerns. The company's strong profitability and solvency are offset by liquidity and efficiency issues. The recent negative growth trends in revenue and earnings are a significant concern that needs attention.
Overall Valuation Score
P/E RATIO (TTM)
11.22
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
11.21
P/B RATIO
1.74
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
1.49
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
7.97
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹102.8 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth metrics indicate significant challenges for Quest Laboratories, with declines in revenue, EPS, and asset growth. Strong operating profit growth is overshadowed by these contractions. The company needs to address the factors causing these declines to ensure sustainable growth and maintain its competitive position.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 96.67 | 5.08 | 33.87 | 25.3 | 7.69 |
| Operating Profit Growth Rate | 500 | 33.33 | 100 | 0 | 12.5 |
| Earnings Per Share (EPS) Growth | -2.01 | 10.75 | |||
| Asset Growth Rate | 94.44 | 34.29 | 29.79 | 100 | -9.02 |
| Net Income Growth Rate | 300 | 25 | 100 | 40 | 7.14 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial metrics present a mixed picture for Quest Laboratories. While capital expenditures are well-managed, earnings per share and book value per share are weak. The absence of dividends further impacts the overall assessment. The company needs to focus on improving earnings and enhancing shareholder value to strengthen its financial position.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 40.2 | 50 | 8.33 | 8.75 | 9.38 |
| Cash Earnings Per Share (Cash EPS) | 40 | 60 | 9.17 | 9.38 | 10 |
| Book Value Per Share | 100 | 150 | 24.17 | 50.62 | 60 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | ||
| Capital Expenditures (CapEx) | 1.9 | 3 | 0.9 | 3.5 | 5.2 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability metrics demonstrate exceptional performance for Quest Laboratories, with strong margins and returns on capital, equity, and assets. This indicates efficient operations and effective management. The company excels in generating profits from its investments and sales, providing a solid foundation for sustainable growth and financial stability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 10.17 | 11.29 | 18.07 | 14.42 | 15.18 |
| Return on Capital Employed (ROCE) | 55 | 47 | 57 | 27 | 18 |
| Return on Equity (ROE) | 40 | 33.33 | 34.48 | 17.28 | 15.62 |
| Return on Assets (ROA) | 17.14 | 17.02 | 26.23 | 13.11 | 16.22 |
| Operating Margin | 10.17 | 12.9 | 19.28 | 15.38 | 16.07 |
| Net Margin | 6.78 | 8.06 | 12.05 | 13.46 | 13.39 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency metrics reveal a mixed performance for Quest Laboratories. While inventory management appears strong, concerns arise from fixed asset and capital turnover. Receivable management also poses challenges. The company excels in inventory management but needs to improve the utilization of its fixed assets and overall capital to enhance operational efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 8.43 | 6.2 | 8.3 | 8.67 | 7.47 |
| Inventory Turnover Ratio | 55.21 | 8.98 | 4.99 | 4.75 | 3.17 |
| Receivables Turnover Ratio | 3.78 | 2.95 | 3.74 | 3.82 | 3.38 |
| Days Sales in Inventory Ratio | 6.61 | 40.65 | 73.15 | 76.84 | 115.14 |
| Receivable Days | 96.56 | 123.73 | 97.59 | 95.55 | 107.99 |
| Capital Turnover Ratio | 5.2 | 3.67 | 2.78 | 1.26 | 1.16 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage ratios are mixed, with adequate interest coverage offset by the absence of dividend coverage. This suggests that Quest Laboratories can comfortably meet its interest obligations but does not provide returns to equity holders through dividends. While interest coverage is solid, the lack of dividend payments may deter potential investors.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | 8 | 15 | 20 | 10 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Quest Laboratories showcases exceptional solvency, with a strong position across debt and equity metrics. This indicates a conservative and stable financial structure. The company has very low debt levels relative to equity and assets, highlighting financial stability and a reduced risk of financial distress. This robust solvency provides a solid foundation for future growth and resilience against economic uncertainties.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.12 | 0.11 | 0.03 | 0.02 | 0.01 |
| Debt to Equity Ratio | 0.14 | 0.12 | 0.03 | 0.02 | 0.01 |
| Equity Ratio | 0.88 | 0.89 | 0.97 | 0.98 | 0.99 |
| Debt To Asset Ratio | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity position is a concern for Quest Laboratories, with a mix of weak and below-average scores across key metrics. The company may face difficulties in meeting its short-term obligations. While the current and quick ratios are low, the minimal cash ratio and operating cash flow ratio further highlight potential liquidity strains. This situation could restrict the company's operational flexibility and its ability to capitalize on immediate growth opportunities.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.13 | 1.22 | 1.41 | 1.49 | 6.09 |
| Quick Ratio | 1.09 | 0.86 | 0.89 | 0.94 | 3.11 |
| Cash Ratio | 0.07 | 0 | 0 | 0 | 0.01 |
| Operating Cash Flow Ratio | 0.13 | 0.13 | 0.1 | -0.59 | -0.85 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Par Drugs & Chemicals Ltd | 7.40 | 8.88 | Undervalued | 17.00 | 10.65 | 13.00 |
| 2 | Vaishali Pharma Ltd | 6.74 | 103.62 | Overvalued | 4.00 | 0.31 | 4.00 |
| 3 | Quest Laboratories Ltd | 5.27 | 11.21 | Neutral | 18.00 | 9.16 | 15.00 |
| 4 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 5 | Zenith Drugs Ltd | 4.63 | 7.52 | Neutral | 17.00 | 2.30 | 10.00 |
| 6 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.27 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
The management of Quest Laboratories demonstrates a mixed performance. The company has shown strong growth in sales and maintains high ROCE and ROE. However, increasing borrowings and a fluctuating cash conversion cycle present concerns. A substantial promoter holding indicates confidence, but the recent investment in assets requires monitoring for optimal returns. Overall, management effectiveness is rated as mixed due to these counterbalancing factors.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Sales Growth | 26% | Sales expansion is robust. |
| High ROCE and ROE | 57.48%, 46.15% | Capital and shareholder funds are yielding good returns. | |
| CONS | Increasing Short Term Borrowings | ₹ 28.89 Cr. | Leverage is increasing. |
| Fluctuating Cash Conversion Cycle | 3 to 178 Days | Working capital management is inconsistent. |
Financial Performance & Growth
Quest Laboratories shows strong financial performance and growth. Compounded sales growth indicates a positive trend. Compounded profit growth is also robust, showing an ability to translate sales into profits effectively.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Sales Growth (%) | 3.63% | 33.94% | 25.86% |
However, the OPM % has fluctuated quarterly, increasing from 9% in Mar 2023 to 27% in Sep 2024, then declining to 8% in Mar 2025. Dependence on other income is minimal, with core operations being the primary profit driver until Mar 2025, where other income contribution increased. The business model looks promising, but the fluctuations in OPM need monitoring.
Capital Efficiency & Returns
Quest Laboratories showcases excellent capital efficiency and returns. The ROCE is consistently high, indicating effective use of capital employed. The ROE is also robust, suggesting good returns on shareholder funds.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROCE (%) | 55% | 47% | 58% | 27% |
| ROE (%) | - | - | - | - |
The cash conversion cycle shows volatility, ranging from 3 days in Mar 2023 to 178 days in Mar 2025, indicating inconsistent working capital management.
Financial Health & Prudence
The financial health and prudence of Quest Laboratories present a mixed picture. Borrowings have increased significantly, particularly short-term borrowings. The Debt/Equity ratio can be assessed using borrowings and equity capital data; however, it is increasing.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Borrowings (₹ Cr) | 4 | 5 | 30 |
The company has maintained a zero dividend payout percentage over the years, retaining all profits, but borrowings have substantially increased from Mar 2024 to Mar 2025.
Shareholding & Ownership Structure
The shareholding and ownership structure of Quest Laboratories indicate stable promoter holding. The promoter holding is significant, indicating confidence in the company's prospects. There is also FII and DII interest in the company, which adds to its credibility. The number of shareholders has increased, indicating growing investor interest.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 65.83% | 65.83% | 66.21% |
| FII Holding (%) | 0.74% | 1.31% | 0.95% |
| DII Holding (%) | 4.44% | 4.86% | 2.07% |
Quest Laboratories faces a moderate risk profile. The increase in short-term borrowings raises concerns about financial leverage. The fluctuating cash conversion cycle suggests potential inefficiencies in working capital management. The lack of dividend payouts might deter some investors. These factors contribute to an overall risk assessment that requires careful monitoring.
Off-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Accounting quality red flags
There is no specific data available on accounting quality red flags.
Segment performance volatility
There is no specific data available on segment performance volatility.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10105.41Bearish
- SMA 20110.23Bearish
- SMA 50105.58Bearish
- EMA 10105.25Bearish
- EMA 20106.93Bearish
- EMA 50106.54Bearish
- DEMA 10102.46Bearish
- DEMA 20105.80Bearish
- DEMA 50107.46Bearish
- TEMA 10101.20Bullish
- TEMA 20103.17Bearish
- TEMA 50108.90Bearish
- MACD-1.28Bearish
- ADX27.01Strong Trend
- IndicatorValueSignal
- RSI36.63Neutral
- CCI-104.78Oversold
- ROC 9-4.32Bearish
- ROC 14-12.82Bearish
- ROC 25-3.41Bearish
- Stoch K7.28Oversold
- Stoch D5.36Oversold
- IndicatorValueSignal
- BB Upper122.16Neutral
- BB Middle110.23Neutral
- BB Lower98.31Neutral
- ATR2.23Low Volatility
- IndicatorValueSignal
- MFI20.18Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10108.08Bearish
- SMA 20107.78Bearish
- SMA 50104.06Bearish
- EMA 10106.30Bearish
- EMA 20106.72Bearish
- EMA 50106.52Bearish
- DEMA 10104.42Bearish
- DEMA 20107.35Bearish
- DEMA 50104.86Bearish
- TEMA 10102.00Bullish
- TEMA 20106.63Bearish
- TEMA 50107.17Bearish
- MACD0.11Bearish
- ADX24.19Weak Trend
- IndicatorValueSignal
- RSI41.42Neutral
- CCI-76.80Neutral
- ROC 9-12.82Bearish
- ROC 14-5.77Bearish
- ROC 25-0.20Bearish
- Stoch K10.46Oversold
- Stoch D18.52Oversold
- IndicatorValueSignal
- BB Upper120.03Neutral
- BB Middle107.78Neutral
- BB Lower95.54Neutral
- ATR3.19Low Volatility
- IndicatorValueSignal
- MFI38.94Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10107.47Bearish
- SMA 20104.11Bearish
- SMA 50107.37Bearish
- EMA 10106.32Bearish
- EMA 20105.93Bearish
- EMA 50108.63Bearish
- DEMA 10106.89Bearish
- DEMA 20105.58Bearish
- DEMA 50103.53Bearish
- TEMA 10106.26Bearish
- TEMA 20107.72Bearish
- TEMA 50N/AN/A
- MACD-0.04Bullish
- ADX23.52Weak Trend
- IndicatorValueSignal
- RSI44.34Neutral
- CCI-24.59Neutral
- ROC 91.90Bullish
- ROC 142.00Bullish
- ROC 251.39Bullish
- Stoch K30.40Neutral
- Stoch D39.40Neutral
- IndicatorValueSignal
- BB Upper114.91Neutral
- BB Middle104.11Neutral
- BB Lower93.32Neutral
- ATR4.58Low Volatility
- IndicatorValueSignal
- MFI75.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10104.14Bearish
- SMA 20106.37Bearish
- SMA 50115.91Bearish
- SMA 100113.59Bearish
- SMA 200103.68Bearish
- EMA 10106.01Bearish
- EMA 20107.40Bearish
- EMA 50111.31Bearish
- EMA 100110.81Bearish
- EMA 200108.39Bearish
- DEMA 10106.14Bearish
- DEMA 20103.48Bearish
- DEMA 50109.02Bearish
- DEMA 100114.21Bearish
- DEMA 200109.54Bearish
- TEMA 10108.17Bearish
- TEMA 20103.75Bearish
- TEMA 50103.95Bearish
- TEMA 100113.46Bearish
- TEMA 200N/AN/A
- MACD-2.53Bullish
- ADX15.25Weak Trend
- IndicatorValueSignal
- RSI44.30Neutral
- CCI-26.94Neutral
- ROC 140.64Bullish
- ROC 25-7.01Bearish
- Stoch K47.92Neutral
- Stoch D53.25Neutral
- IndicatorValueSignal
- BB Upper120.70Neutral
- BB Middle106.37Neutral
- BB Lower92.03Neutral
- ATR6.72High Volatility
- IndicatorValueSignal
- MFI70.03Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20114.99Bearish
- SMA 50103.31Bearish
- EMA 20112.27Bearish
- EMA 50109.02Bearish
- DEMA 20116.02Bearish
- DEMA 50109.38Bearish
- TEMA 20115.05Bearish
- TEMA 50N/AN/A
- MACD2.08Bearish
- ADX26.12Strong Trend
- IndicatorValueSignal
- RSI47.32Neutral
- CCI-17.07Neutral
- ROC 14-8.30Bearish
- ROC 25-7.08Bearish
- Stoch K14.07Oversold
- Stoch D18.08Oversold
- IndicatorValueSignal
- BB Upper140.43Neutral
- BB Middle114.99Neutral
- BB Lower89.55Neutral
- ATR13.87Low Volatility
- IndicatorValueSignal
- MFI53.54Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
No results for this timeframe
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6117.13Bearish
- SMA 12105.45Bullish
- SMA 24112.48Bullish
- EMA 6117.85Bearish
- EMA 12112.92Bullish
- EMA 24112.95Bullish
- DEMA 6125.71Bearish
- DEMA 12116.24Bullish
- DEMA 24N/AN/A
- TEMA 6129.36Bearish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADXN/AN/A
- IndicatorValueSignal
- RSIN/AN/A
- CCIN/AN/A
- ROC 25N/AN/A
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper144.01Neutral
- BB Middle108.89Neutral
- BB Lower73.76Neutral
- ATR30.39High Volatility
- IndicatorValueSignal
- MFI48.99Neutral